

Charles S Landis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2909699/publications.pdf>

Version: 2024-02-01

23
papers

2,051
citations

623734

14
h-index

677142

22
g-index

24
all docs

24
docs citations

24
times ranked

3028
citing authors

#	ARTICLE	IF	CITATIONS
1	Renal Outcomes With Tenofovir Alafenamide in Liver Transplant Recipients. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 538-540.e4.	4.4	2
2	Treatment and Renal Outcomes Up to 96 Weeks After Tenofovir Alafenamide Switch From Tenofovir Disoproxil Fumarate in Routine Practice. <i>Hepatology</i> , 2021, 74, 656-666.	7.3	31
3	Evaluation of ethnic influence in the application of a hepatocellular carcinoma predictive model for chronic hepatitis C. <i>Journal of Medical Virology</i> , 2021, 93, 6257-6266.	5.0	0
4	Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 918-926.	8.1	28
5	DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort. <i>Journal of Hepatology</i> , 2020, 73, 540-548.	3.7	85
6	Wirelessly Observed Therapy to Optimize Adherence and Target Interventions for Oral Hepatitis C Treatment: Observational Pilot Study. <i>Journal of Medical Internet Research</i> , 2020, 22, e15532.	4.3	12
7	Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial. <i>Journal of Hepatology</i> , 2019, 70, 483-493.	3.7	124
8	Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1811-1819.e4.	4.4	20
9	2220. Wirelessly Observed Therapy with a Digital Medicines Program to Optimize Adherence and Target Interventions for Oral Hepatitis C Treatment. <i>Open Forum Infectious Diseases</i> , 2018, 5, S656-S656.	0.9	5
10	Can we mitigate the effects of simultaneous liver-kidney transplantation through increased utilization of HCV-positive donors?. <i>American Journal of Transplantation</i> , 2018, 18, 2604-2605.	4.7	1
11	Deferred treatment with sofosbuvir+velpatasvir+voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 559-565.	8.1	27
12	Expanding access to transplantation with hepatitis C+positive donors: A new perspective on an old issue. <i>Clinical Transplantation</i> , 2017, 31, e12884.	1.6	11
13	Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment. <i>Hepatology</i> , 2017, 66, 389-397.	7.3	172
14	Biopsy Specimens From Allograft Liver Contain Histologic Features of Hepatitis C Virus Infection After Virus Eradication. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1279-1285.	4.4	30
15	IRE1 α promotes viral infection by conferring resistance to apoptosis. <i>Science Signaling</i> , 2017, 10, .	3.6	33
16	High antiviral activity of NS5A inhibitor ABT530 with paritaprevir/ritonavir and ribavirin against hepatitis C virus genotype 3 infection. <i>Liver International</i> , 2016, 36, 1125-1132.	3.9	14
17	Management of Post-Liver Transplant Recurrence of Hepatitis C. <i>Drugs</i> , 2016, 76, 1711-1717.	10.9	4
18	Aging of Liver Transplant Registrants and Recipients: Trends and Impact on Waitlist Outcomes, Post-Transplantation Outcomes, and Transplant-Related Survival Benefit. <i>Gastroenterology</i> , 2016, 150, 441-453.e6.	1.3	150

#	ARTICLE	IF	CITATIONS
19	Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. <i>Hepatology</i> , 2016, 63, 1493-1505.	7.3	397
20	Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report. <i>Journal of Medical Case Reports</i> , 2015, 9, 164.	0.8	93
21	Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. <i>Gastroenterology</i> , 2015, 149, 649-659.	1.3	725
22	Portal Vein Thrombosis Is Not Associated With Increased Mortality Among Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 585-593.	4.4	79
23	Liver regeneration and energetic changes in rats following hepatic radiation therapy and hepatocyte transplantation by ³¹ P MRSI. <i>Liver International</i> , 2015, 35, 1145-1151.	3.9	8